Xbiotech announces enrollment completion of phase i clinical trial for hutrukin, a novel candidate therapy for stroke

Austin, texas, sept. 26, 2023 (globe newswire) -- xbiotech inc. (nasdaq: xbit) announces that hutrukin is being developed by xbiotech as a breakthrough therapy to reduce brain injury after stroke. the last subject in a randomized, open-label, placebo-controlled phase i dose escalation clinical study has been enrolled. xbiotech discovered, manufactures, and is conducting this clinical study of hutrukin.
XBIT Ratings Summary
XBIT Quant Ranking